{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:41:20Z","timestamp":1792604480137,"version":"4.5.0"},"reference-count":33,"publisher":"MyJove Corporation","issue":"205","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/66071","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T20:01:34Z","timestamp":1711742494000},"source":"Crossref","is-referenced-by-count":0,"title":["&lt;em&gt;Ex Vivo&lt;\/em&gt; Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease"],"prefix":"10.3791","author":[{"given":"Vincent","family":"Law","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Smalley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany R.","family":"Evernden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiran S. M.","family":"Smalley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Forsyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2024,3,29]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/pcmr.12861","type":"journal-article","article-title":"Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions","volume":"33","author":"Glitza","year":"2020","unstructured":"Glitza, I. C. et al. Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. Pigment Cell Melanoma Res. 33 (4), 527-541 (2020).","journal-title":"Pigment Cell Melanoma Res"},{"issue":"6","key":"ref2","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.3390\/cancers15061884","type":"journal-article","article-title":"Leptomeningeal disease (LMD) in patients with melanoma metastases","volume":"15","author":"Khaled","year":"2023","unstructured":"Khaled, M. L., Tarhini, A. A., Forsyth, P. A., Smalley, I., Pina, Y. Leptomeningeal disease (LMD) in patients with melanoma metastases. Cancers (Basel). 15 (6), 1884 (2023).","journal-title":"Cancers (Basel)"},{"issue":"9","key":"ref3","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1158\/1078-0432.CCR-19-2840","type":"journal-article","article-title":"Proteomic analysis of CSF from patients with leptomeningeal melanoma metastases identifies signatures associated with disease progression and therapeutic resistance)","volume":"26","author":"Smalley","year":"2020","unstructured":"Smalley, I. et al. Proteomic analysis of CSF from patients with leptomeningeal melanoma metastases identifies signatures associated with disease progression and therapeutic resistance. Clin Cancer Res. 26 (9), 2163-2175 (2020).","journal-title":"Clin Cancer Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","type":"journal-article","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","unstructured":"Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 381, 1535-1546 (2019).","journal-title":"N Engl J Med"},{"issue":"6","key":"ref5","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.cell.2017.02.025","type":"journal-article","article-title":"Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis","volume":"168","author":"Boire","year":"2017","unstructured":"Boire, A. et al. Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis. Cell. 168 (6), 1101-1113 e1113 (2017).","journal-title":"Cell"},{"issue":"6501","key":"ref6","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1126\/science.aaz2193","type":"journal-article","article-title":"Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis","volume":"369","author":"Chi","year":"2020","unstructured":"Chi, Y. et al. Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis. Science. 369 (6501), 276-282 (2020).","journal-title":"Science"},{"issue":"10","key":"ref7","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/neuonc\/noac054","type":"journal-article","article-title":"A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma","volume":"24","author":"Law","year":"2022","unstructured":"Law, V. et al. A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma. Neuro Oncol. 24 (10), 1673-1686 (2022).","journal-title":"Neuro Oncol"},{"issue":"11","key":"ref8","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.3390\/cancers13112668","type":"journal-article","article-title":"Short-term ex vivo culture of CTCs from advance breast cancer patients: Clinical implications","volume":"13","author":"Carmona-Ule","year":"2021","unstructured":"Carmona-Ule, N. et al. Short-term ex vivo culture of CTCs from advance breast cancer patients: Clinical implications. Cancers (Basel). 13 (11), 2668 (2021).","journal-title":"Cancers (Basel)"},{"issue":"180","key":"ref9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005109","type":"journal-article","article-title":"The identification and characterization of breast cancer CTCs competent for brain metastasis","volume":"5","author":"Zhang","year":"2013","unstructured":"Zhang, L. et al. The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med. 5 (180), 180ra148 (2013).","journal-title":"Sci Transl Med"},{"issue":"6193","key":"ref10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1126\/science.1253533","type":"journal-article","article-title":"Cancer therapy: Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility","volume":"345","author":"Yu","year":"2014","unstructured":"Yu, M. et al. Cancer therapy: Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. 345 (6193), 216-220 (2014).","journal-title":"Science"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1038\/s41598-023-30733-6","type":"journal-article","article-title":"Ex vivo expansion of circulating tumour cells (CTCs)","volume":"13","author":"Mohamed","year":"2023","unstructured":"Mohamed, B. M. et al. Ex vivo expansion of circulating tumour cells (CTCs). Sci Rep. 13 (1), 3704 (2023).","journal-title":"Sci Rep"},{"issue":"2","key":"ref12","first-page":"92","type":"journal-article","article-title":"Meninges: From protective membrane to stem cell niche","volume":"1","author":"Decimo","year":"2012","unstructured":"Decimo, I., Fumagalli, G., Berton, V., Krampera, M., Bifari, F. Meninges: From protective membrane to stem cell niche. Am J Stem Cells. 1 (2), 92-105 (2012).","journal-title":"Am J Stem Cells"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/1096-9861(20010226)431:1<88::AID-CNE1057>3.0.CO;2-D","type":"journal-article","article-title":"Connexin 26 and basic fibroblast growth factor are expressed primarily in the subpial and subependymal layers in adult brain parenchyma: Roles in stem cell proliferation and morphological plasticity","volume":"431","author":"Mercier","year":"2001","unstructured":"Mercier, F., Hatton, G. I. Connexin 26 and basic fibroblast growth factor are expressed primarily in the subpial and subependymal layers in adult brain parenchyma: Roles in stem cell proliferation and morphological plasticity? J Comp Neurol. 431 (1), 88-104 (2001).","journal-title":"J Comp Neurol"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1073\/pnas.85.1.141","type":"journal-article","article-title":"Expression of the insulin-like growth factor II gene in the choroid plexus and the leptomeninges of the adult rat central nervous system","volume":"85","author":"Stylianopoulou","year":"1988","unstructured":"Stylianopoulou, F., Herbert, J., Soares, M. B., Efstratiadis, A. Expression of the insulin-like growth factor II gene in the choroid plexus and the leptomeninges of the adult rat central nervous system. Proc Natl Acad Sci U S A. 85 (1), 141-145 (1988).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1023\/A:1015765613544","type":"journal-article","article-title":"Expression of IGF-II, IGFBP-2, -5, and -6 in meningiomas with different brain invasiveness","volume":"5","author":"Nordqvist","year":"2002","unstructured":"Nordqvist, A. C., Mathiesen, T. Expression of IGF-II, IGFBP-2, -5, and -6 in meningiomas with different brain invasiveness. J Neurooncol. 57, 19-26 (2002).","journal-title":"J Neurooncol"},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/mp.54.4.227","type":"journal-article","article-title":"The IGF\/IGFBP system in CNS malignancy","volume":"54","author":"Zumkeller","year":"2001","unstructured":"Zumkeller, W., Westphal, M. The IGF\/IGFBP system in CNS malignancy. Mol Pathol. 54 (4), 227-229 (2001).","journal-title":"Mol Pathol"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/j.seminoncol.2016.06.004","type":"journal-article","article-title":"Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells","volume":"43","author":"Wang","year":"2016","unstructured":"Wang, L. et al. Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells. Semin Oncol. 43 (4), 464-475 (2016).","journal-title":"Semin Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","type":"journal-article","article-title":"Patient-derived xenograft models in cancer therapy: technologies and applications","volume":"8","author":"Liu","year":"2023","unstructured":"Liu, Y. et al. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct Target Ther. 8, 160 (2023).","journal-title":"Signal Transduct Target Ther"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1007579","DOI":"10.3389\/fimmu.2022.1007579","type":"journal-article","article-title":"The development and improvement of immunodeficient mice and humanized immune system mouse models","volume":"13","author":"Chen","year":"2022","unstructured":"Chen, J. et al. The development and improvement of immunodeficient mice and humanized immune system mouse models. Front Immunol. 13, 1007579 (2022).","journal-title":"Front Immunol"},{"issue":"167","key":"ref20","first-page":"e62033","type":"journal-article","article-title":"A Murine Ommaya xenograft model to study direct-targeted therapy of leptomeningeal disease","author":"Law","year":"2021","unstructured":"Law, V. et al. A Murine Ommaya xenograft model to study direct-targeted therapy of leptomeningeal disease. J Vis Exp. 167, e62033 (2021).","journal-title":"J Vis Exp"},{"issue":"7","key":"ref21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2310\/7290.2013.00062","type":"journal-article","article-title":"NanoLuc reporter for dual luciferase imaging in living animals","volume":"12","author":"Stacer","year":"2013","unstructured":"Stacer, A. C. et al. NanoLuc reporter for dual luciferase imaging in living animals. Mol Imaging. 12 (7), 1-13 (2013).","journal-title":"Mol Imaging"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13046-018-0685-7","type":"journal-article","article-title":"The viable circulating tumor cells with cancer stem cells feature, where is the way out","volume":"37","author":"Luo","year":"2018","unstructured":"Luo, Y. T. et al. The viable circulating tumor cells with cancer stem cells feature, where is the way out? J Exp Clin Cancer Res. 37, 38 (2018).","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/cne.21336","type":"journal-article","article-title":"Patterns of SDF-1alpha and SDF-1gamma mRNAs, migration pathways, and phenotypes of CXCR4-expressing neurons in the developing rat telencephalon","volume":"502","author":"Stumm","year":"2007","unstructured":"Stumm, R., Kolodziej, A., Schulz, S., Kohtz, J. D., Hollt, V. Patterns of SDF-1alpha and SDF-1gamma mRNAs, migration pathways, and phenotypes of CXCR4-expressing neurons in the developing rat telencephalon. J Comp Neurol. 502 (3), 382-399 (2007).","journal-title":"J Comp Neurol"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/0092-8674(94)90031-0","type":"journal-article","article-title":"basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis","volume":"79","author":"Aviezer","year":"1994","unstructured":"Aviezer, D. et al. Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell. 79 (6), 1005-1013 (1994).","journal-title":"Cell"},{"issue":"7","key":"ref25","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1038\/oncsis.2014.23","type":"journal-article","article-title":"ERBB3 is required for metastasis formation of melanoma cells","volume":"3","author":"Tiwary","year":"2014","unstructured":"Tiwary, S. et al. ERBB3 is required for metastasis formation of melanoma cells. Oncogenesis. 3 (7), e110 (2014).","journal-title":"Oncogenesis"},{"issue":"33","key":"ref26","doi-asserted-by":"crossref","first-page":"53558","DOI":"10.18632\/oncotarget.10669","type":"journal-article","article-title":"miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR\/IGF-1R\/CRAF and inhibiting the MAPK and PI3K\/AKT signaling pathways","volume":"7","author":"Sun","year":"2016","unstructured":"Sun, X. et al. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR\/IGF-1R\/CRAF and inhibiting the MAPK and PI3K\/AKT signaling pathways. Oncotarget. 7 (33), 53558-53570 (2016).","journal-title":"Oncotarget"},{"issue":"19","key":"ref27","first-page":"7318","type":"journal-article","article-title":"Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways","volume":"61","author":"Satyamoorthy","year":"2001","unstructured":"Satyamoorthy, K., Li, G., Vaidya, B., Patel, D., Herlyn, M. Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. Cancer Res. 61 (19), 7318-7324 (2001).","journal-title":"Cancer Res"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaoncol.2022.5610","type":"journal-article","article-title":"Tucatinib vs Placebo, both in combination with Trastuzumab and Capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: Updated exploratory analysis of the HER2CLIMB randomized clinical trial","volume":"9","author":"Lin","year":"2023","unstructured":"Lin, N. U. et al. Tucatinib vs Placebo, both in combination with Trastuzumab and Capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: Updated exploratory analysis of the HER2CLIMB randomized clinical trial. JAMA Oncol. 9 (2), 197-205 (2023).","journal-title":"JAMA Oncol"},{"issue":"17","key":"ref29","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.3390\/ijms20174267","type":"journal-article","article-title":"Ceritinib-induced regression of an insulin-like growth factor-driven neuroepithelial brain tumor","volume":"20","author":"Russo","year":"2019","unstructured":"Russo, A. et al. Ceritinib-induced regression of an insulin-like growth factor-driven neuroepithelial brain tumor. Int J Mol Sci. 20 (17), 4267 (2019).","journal-title":"Int J Mol Sci"},{"issue":"5","key":"ref30","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1600-0560.2007.00891.x","type":"journal-article","article-title":"Immunohistochemical characteristics of melanoma","volume":"35","author":"Ohsie","year":"2008","unstructured":"Ohsie, S. J., Sarantopoulos, G. P., Cochran, A. J., Binder, S. W. Immunohistochemical characteristics of melanoma. J Cutan Pathol. 35 (5), 433-444 (2008).","journal-title":"J Cutan Pathol"},{"issue":"37","key":"ref31","doi-asserted-by":"crossref","first-page":"60101","DOI":"10.18632\/oncotarget.11159","type":"journal-article","article-title":"Short term ex-vivo expansion of circulating head and neck tumour cells","volume":"7","author":"Kulasinghe","year":"2016","unstructured":"Kulasinghe, A. et al. Short term ex-vivo expansion of circulating head and neck tumour cells. Oncotarget. 7 (37), 60101-60109 (2016).","journal-title":"Oncotarget"},{"issue":"2","key":"ref32","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.18632\/oncotarget.23597","type":"journal-article","article-title":"Clinical significance of detecting CSF-derived tumor cells in breast cancer patients with leptomeningeal metastasis","volume":"9","author":"Li","year":"2018","unstructured":"Li, X. et al. Clinical significance of detecting CSF-derived tumor cells in breast cancer patients with leptomeningeal metastasis. Oncotarget. 9 (2), 2705-2714 (2018).","journal-title":"Oncotarget"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/s41598-018-37883-y","type":"journal-article","article-title":"A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy","volume":"9","author":"Lelliott","year":"2019","unstructured":"Lelliott, E. J. et al. A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy. Sci Rep. 9 (1), 1225 (2019).","journal-title":"Sci Rep"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jove.com\/t\/66071\/ex-vivo-culture-circulating-tumor-cells-cerebral-spinal-fluid-from","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:06:37Z","timestamp":1792602397000},"score":1,"resource":{"primary":{"URL":"https:\/\/app.jove.com\/t\/66071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,29]]},"references-count":33,"journal-issue":{"issue":"205","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.3791\/66071","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,29]]}}}